openPR Logo
Press release

BellaSeno and Charite - Universitaetsmedizin Berlin Collaborate Under BMBF-Funded SyMBoD Consortium

03-24-2020 04:16 PM CET | Health & Medicine

Press release from: BellaSeno GmbH

/ PR Agency: akampion
- Development of absorbable implants for the personalized treatment of bone defects in patients with diabetes
- BellaSeno responsible for high resolution, medical-grade scaffold manufacturing under ISO 13485

Leipzig, Germany, March 24, 2020 - BellaSeno GmbH, a company developing absorbable scaffolds using additive manufacturing technologies, today announced a collaboration with Charite - Universitaetsmedizin Berlin under the recently established SyMBoD consortium. Under the agreement, BellaSeno will design and manufacture personalized, 3D-printed, absorbable implants suitable for the treatment of diabetes patients with bone defects. The goal is to restore blood supply and facilitate the regeneration of persistent bone defects that do not heal otherwise. The consortium is an interdisciplinary project covering innovative digital technology based on systems medicine and precise, reproducible additive manufacturing. Within the consortium, BellaSeno is fully responsible for ISO 13485-compliant, medical-grade scaffold manufacturing.

"Current research suggests that 3D-printed scaffolds, which have been optimized mechanically and biologically, can improve bone regeneration," said Dr. Navid Khani, Head of R&D of BellaSeno. "Our custom-made, high-speed additive manufacturing platform is very precise, generates highly reproducible structures and has been certified according to ISO 13485 standard. We are therefore very well positioned to produce state-of-the-art, medical-grade scaffolds for a variety of applications. This is the first project underlining our manufacturing capabilities for external industry and academic partners."

"We have selected BellaSeno because of the team's unique expertise in additive manufacturing of porous structures with extremely small features as required for our intended application," said Dr. Su Ping Patrina Poh of Charite's Julius Wolff Institute (JWI). "This strategic inclusion of BellaSeno is also driven by the fact that, to our knowledge, they are the only company within Germany with the capability to perform the entire additive design and manufacturing process chain with ISO13485 certified processes, which is highly aligned with our intention of clinical translation in the future."

BellaSeno is producing 3D-printed absorbable implants in very high-resolution lattice-based structures using melt-extrusion technology. While numerous companies can manufacture porous structures using 3D-printing technologies, it is extremely challenging to reproducibly generate structures if the required unit-cell size is less than 3 mm. Using its custom-built Yasham additive manufacturing platform, BellaSeno can reproducibly and routinely manufacture scaffolds with unit cell sizes down to about 1 mm.

The SyMBoD consortium consists of 4 universities and 1 industry partner and is dedicated to developing novel, personalized treatments for endogenous bone regeneration in patients with diabetes. Funded by Germany's Ministry for Education and Research (BMBF) and led by Charite Universitaetsmedizin Berlin, the project includes partner institutions such as University of Freiburg, Fraunhofer IZI, Technical University of Munich, and Genvention GmbH. SyMBoD is part of BMBF's e:Med initiative, which is supporting various system medicine consortia with a total budget of EUR 200 million over the course of eight years.

###

Contact BellaSeno
BellaSeno GmbH
Deutscher Platz 5a (BioCity)
04103 Leipzig
Germany
Dr. Mohit P. Chhaya
mohit.chhaya@bellaseno.com
Tel.: +49 176 2283 9583

Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info(at)akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

About BellaSeno

BellaSeno GmbH was founded in 2015 and is located on the BioCity campus in Leipzig, Germany. The Company is developing novel absorbable implants made by additive manufacturing (3D-printing) as well as providing contract manufacturing services under ISO 13485. The Company has received substantial financial support from private investors as well as from the Saxony Development Bank (SAB) and the European Fund for Regional Development (EFRE). The Company is thereby co-funded from tax resources based on the budget adopted by the members of Saxon State Parliament.

About Charite - Universitaetsmedizin Berlin
Charite - Universitaetsmedizin Berlin is one of the largest university hospitals in Europe, boasting approximately 100 departments and institutes spread across 4 separate campuses. The hospital offers a total of 3,001 beds and, in 2018, treated 152,693 in- and day case patients, in addition to 692,920 outpatients. At Charite, the areas of research, teaching and medical care are closely interlinked. With approximately 18,000 members of staff employed across its group of companies, Charite is one of the largest employers in Berlin. More than 4,500 of its employees work in the field of nursing, and around 4,300 in research and medical care. In 2018, Charite recorded a turnover of more than EUR1.8 billion, and set a new record by securing more than EUR170.9 million in external funding. Charite's Medical Faculty is one of the largest in Germany, educating and training more than 7,500 medical and dentistry students. Charite also offers 619 training positions across 9 different health care professions. http://www.charite.de

About e:Med
e:Med, the new Federal Ministry of Education and Research (BMBF) nationwide research program, promotes system-oriented research into diseases, in order to facilitate improved prevention, more comprehensive diagnostics and individually adjusted therapy schemes in individualized medicine. "e:Med" stands for the electronic processing and integration of medically relevant data from diverse levels of knowledge in systems medicine. Establishing systems medicine in Germany is the objective of researchers who have joined forces in e:Med. The Federal Ministry of Education and Research is funding e:Med with up to 200 million euro, initially for eight years.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release BellaSeno and Charite - Universitaetsmedizin Berlin Collaborate Under BMBF-Funded SyMBoD Consortium here

News-ID: 1981496 • Views: 367

More Releases from BellaSeno GmbH

BellaSeno Initiates Scaffold Development Program for Tendon and Ligament Regener …
- Collaboration with Fraunhofer IZI further expanded - Funding provided by Sächsische Aufbaubank Leipzig, Germany, July 1, 2021 – BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that the Company has initiated a program on tendon and ligament reconstruction funded by the State of Saxony´s Sächsische Aufbaubank (SAB). The program will be run in close collaboration with Fraunhofer Institute for Cell Therapy and Immunology
BellaSeno Wins Prestigious German Innovation Award 2021
- Leading-edge Senella® soft tissue technology awarded for excellence in B2B / medical technologies Leipzig, Germany, May 18, 2021 – BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that the Company has received the German Innovation Award from the German Design Council for its Senella® technology in the category #W2 Excellence in Business to Business - Medical Technologies. BellaSeno has been chosen among
BellaSeno Establishes GMP-Compliant High-Throughput Additive Manufacturing Facil …
- Seamless transition from R&D to commercial-scale additive manufacturing - Leading-edge cleanroom, no-touch manufacturing - GMP capabilities for internal and contract manufacturing Leipzig, Germany, November 17, 2020 - BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the establishment of a novel, leading-edge additive manufacturing facility for medical implants supported by the Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany. It is the one
Evonik and BellaSeno partner to enable the launch of an innovative 3D printed br …
- 3D printed breast scaffolds to be made of RESOMER® - Degradation of RESOMER® to match the growth of the patient’s own tissue for natural breasts - Technology designed to improve quality of life for patients after breast reconstruction and augmentation - Human clinical trials to commence later this year Evonik, a global leader in biomaterials for implantable medical devices, and BellaSeno GmbH, a developer of 3D printed absorbable scaffolds, today announced the signing

All 5 Releases


More Releases for Charite

Outpatient Surgical Procedures Market 2022 Industry Size, Recent Trends, Demand …
The global outpatient surgical procedures sector is expected to rise by USD 149 billion with a CAGR of 6.8% during the forecast period. Outpatient Surgical Procedures Market 2022 research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current
Muckle-Wells Syndrome Market 2020 Competitive Analysis by Istituto Giannina Gasl …
Muckle-Wells Syndrome Market report involves the drivers and restraints for the market that are derived from SWOT analysis, and also shows what all the recent developments, product launches, joint ventures, mergers and acquisitions by the several key players and brands that are driving the market are by systemic company profiles. Intricate market insights are turned into simpler version in this report with the help of proven tools and techniques to
Development Strategies for Cardiac Assist Device Market Is Expected To Generate …
The 'Global Cardiac Assist Device Industry, 2014-2024 Market Research Report' is a professional and in-depth study on the current state of the Global Cardiac Assist Device Market with a focus on the Chinese market. The report provides key statistics on the market status of the Cardiac Assist Device manufacturer and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides
Central Venous Catheters - Medical Devices Pipeline Assessment, 2017
"The Report Central Venous Catheters - Medical Devices Pipeline Assessment, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Central Venous Catheters market Summary GlobalData's Medical Devices sector report, Central Venous Catheters - Medical Devices Pipeline Assessment, 2017" provides an overview of Central Venous Catheters currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products
Muckle-Wells Syndrome Market Will Reflect Significant Growth Prospects during 20 …
Muckle-Wells Syndrome (MWS) is a rare, genetic autosomal disease which leads to urticaria, sensorineural deafness, and also leads to amyloidosis. The disease is mainly caused due to mutation of CIAS1 gene, that leads to increased production of interleukin 1B. Due to interaction of IL1B and skin receptors, the inflammation occurs, which leads to fever and rashes. The common symptoms include fevers, chills, deafness, arthritis, and recurrent urticaria.The episode of MWS
Long Term Survival after Combined Liver- and Kidney Transplantation
"Combined liver and kidney transplantation is an established therapeutic option in patients with profound and irreversible liver and kidney failure. Patients with hepatitis B or C and chronic renal failure, with polycystic liver and kidney disease and patients with primary hyperoxaluria typ I (pHI) are the main groups of patients qualifying for this operation," Dr. M. Oppert and colleagues (Charite/Virchow, Berlin) report (Transplantationsmedizin). "We retrospectively evaluated long-term survival of 68 patients